Cancer Family
Mixed Neoplasm
CI-CAN-00000030Explore in graph →
Non-malignant109 active trials1 approved drugs4 evidence items
- NCIt
- C6930
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000030Explore in graph →
Clinical trials
451 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03810651 | Pencil Beam Scanning in Patients With Renal Tumors | recruiting | Early Phase 1 | 28 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04308330 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies(NYMC195) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02800486 | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | recruiting | Phase 2 | 37 | Northwell HealthOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05384821 | Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)(MetroWilms) | recruiting | Phase 1 / Phase 2 | 28 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06483048 | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | recruiting | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03868475 | Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions(VAPEX) | withdrawn | N/A | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04423484 | Therapeutic Recommendations for Nephroblastoma(GFANEPHRO20) | recruiting | — | 1,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 | clinicaltrials |
| NCT05984667 | C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors(C-SMART) | completed | — | 32 | Virginia Commonwealth UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07394413 | Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas(SHAFT) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04122872 | GISAR German Interdisciplinary Sarcoma Registry(GISAR) | recruiting | — | 9,000 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05542407 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | recruiting | Phase 1 | 58 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT04574635 | Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer | active not recruiting | — | 18 | Mayo ClinicOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05564026 | Molecular Epidemiology of Pediatric Germ Cell Tumors | recruiting | — | 1,151 | Children's Oncology GroupNETWORK | 1 | Oct 24, 2025 | clinicaltrials |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | HiFiBiO TherapeuticsINDUSTRY | 2 | Oct 22, 2025 | clinicaltrials |
| NCT04106414 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | active not recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT01935934 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 2 | Oct 1, 2025 | clinicaltrials |
| NCT01849952 | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | terminated | — | 94 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05195411 | Vascular Thrombus Involvement in Nephroblastoma(VIN) | completed | — | 72 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.(PASCA) | active not recruiting | N/A | 500 | Centre Leon BerardOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04681248 | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | no longer available | — | — | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03395080 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma(P204) | completed | Phase 2 | 111 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04458597 | Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. | completed | N/A | 23 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 1, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 15, 2026source: clinicaltrials